Bristol-Myers Squibb Co vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Bristol-Myers Squibb Co trades at $63.63 (market cap $129.94B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.27. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals.
| BMY | SPXL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $296.39 |
52-Week Low | $42.60 | $170.20 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
SPXL trades at $295.39, down 0.27% in the last session, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 70. The stock's pivot point at $294 and resistance at $296 suggest near-term price sensitivity. Recent news highlights S&P 500 record highs and AI-driven earnings optimism, though valuation concerns persist.
Outlook remains cautiously optimistic amid strong market momentum, with opportunities from AI growth and corporate earnings, but risks include high valuations and potential pullbacks. Investors should balance bullish technicals with fundamental prudence.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →